세계의 조현병 시장 보고서(2025년)

Schizophrenia is a severe and long-term mental illness that significantly affects an individual's cognitive processes, emotional expression, behavior, and their perception of reality. Symptoms may include delusions, hallucinations, disordered speech, and unusual movements. The comprehensive management of schizophrenia involves a combination of pharmaceutical treatments, rehabilitation programs, and supportive services.

Schizophrenia can manifest in different forms, including catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. Catatonic schizophrenia is a subtype characterized by severe motor disturbances, such as catatonia, immobility, and abnormal postures or movements. Treatment typically involves antipsychotic medications and supportive therapies to manage psychotic symptoms and address catatonic motor behavior. Available treatments encompass first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs that can be administered through oral or injectable routes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The schizophrenia market research report is one of a series of new reports from The Business Research Company that provides schizophrenia market statistics, including schizophrenia industry global market size, regional shares, competitors with a schizophrenia market share, detailed schizophrenia market segments, market trends, and opportunities and any further data you may need to thrive in the schizophrenia industry. This schizophrenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The schizophrenia market size has grown steadily in recent years. It will grow from $5.82 billion in 2024 to $6.06 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to growing demand for effective treatments, mental health awareness, government initiatives, growing research and development.

The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $7.49 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing personalized medicine, growing digital health solutions, growing improved antipsychotic medications, expanding access to healthcare services. Major trends in the forecast period include new drug development, growing emphasis on early intervention, recovery-oriented cares, expanding clinical trials pipeline for schizophrenia treatments.

The forecast of 5.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of clozapine therapy by inflating prices of patented formulations developed in the UK and Germany, resulting in delayed care transitions and higher psychiatric unit costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of mental illness is expected to fuel the expansion of the schizophrenia market in the future. Mental illness encompasses a broad spectrum of mental health conditions that impact a person's cognition, emotions, mood, and behavior, significantly affecting their daily life and interpersonal relationships. The rise in mental health cases has spurred advancements in the treatment of schizophrenia and the development of new medications, thereby contributing to the market's growth. For instance, as of March 2023, data from the National Institute of Mental Health (NIMH), a department of health and human services in the United States, indicated that an estimated 57.8 million adults aged 18 and older had experienced any mental illness (AMI), constituting 22.8% of all adults in the United States. Among different age groups, young adults aged 18-25 years exhibited the highest prevalence of AMI at 33.7%, followed by those aged 26-49 years (28.1%), and individuals aged 50 and above (15.0%). Consequently, the escalating burden of mental illness is expected to be a driving force behind the growth of the schizophrenia market.

The increasing demand for anxiety treatment is expected to drive the growth of the schizophrenia market in the future. Anxiety treatment encompasses various therapeutic approaches and interventions designed to help individuals manage and alleviate excessive and debilitating anxiety symptoms. This treatment can be particularly beneficial for those with schizophrenia, as it addresses comorbid anxiety symptoms that often accompany the disorder and can help reduce the intensity of psychotic symptoms such as hallucinations and delusions. For example, in May 2024, a report by the American Psychiatric Association, a U.S.-based professional organization for psychologists, indicated that in 2024, 43% of adults reported feeling more anxious, up from 37% in 2023 and 32% in 2022, showing a steady rise in anxiety levels. Therefore, the growing demand for anxiety treatment is contributing to the expansion of the schizophrenia market.

Prominent companies in the schizophrenia market are embracing emerging technologies like automated psychological therapy to bolster their market presence. Automated psychological therapy involves utilizing technology, including virtual reality (VR), to offer psychological therapy in an autonomous or self-guided manner. For example, in April 2022, OxfordVR Limited, a digital therapeutic company based in Switzerland, introduced the gameChangeVR technology-a 6-week automated VR treatment that delivers cognitive behavioral therapy (CBT) within secure and immersive virtual environments. This VR-based automated psychological therapy replaces real-life therapists with a virtual coach, enabling the treatment to reach a broader range of patients. Notably, this marks the first instance where digital therapy of any kind has demonstrated efficacy in treating individuals with schizophrenia and mood disorders who experience psychotic symptoms.

In March 2023, Royalty Pharma PLC, a US-based purchaser of biopharmaceutical royalties, completed the acquisition of the royalty rights for the KarXT schizophrenia treatment from Karuna Therapeutics Inc., for a sum of $500 million. As part of this agreement, Royalty Pharma will provide PureTech with a 3% royalty on Karuna's annual sales, up to $2 billion. This acquisition also provides PureTech with additional capital to advance its internal pipeline, including ongoing clinical initiatives, with the potential for future commercialization. KarXT is an investigational oral medication specifically developed for the treatment of schizophrenia and other neurological disorders, focusing on M1/M4-preferred muscarinic agonists. Karuna Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, specializes in the development of pharmaceuticals for psychiatric disorders and schizophrenia.

Major companies operating in the schizophrenia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Holdings Co. Ltd., Biogen Inc., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck A/S, Neurocrine Biosciences Inc., Torrent Pharmaceutical Ltd., Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., PsychoGenics Inc., Karuna Therapeutics Inc., Minerva Neurosciences Inc.

North America was the largest region in the schizophrenia market in 2024. The regions covered in the schizophrenia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the schizophrenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The schizophrenia market consists of revenues earned by entities by providing cognitive behavioral therapy, electroconvulsive therapy, and group counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizophrenia market also includes sales of risperdal, invega, zyprexa, geodon and seroquel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizophrenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizophrenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizophrenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The schizophrenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Catatonic Schizophrenia; Paranoid Schizophrenia; Undifferentiated Schizophrenia; Hebephrenic Schizophrenia; Residual Schizophrenia; Other Types
• 2) By Treatment: First-Generation Antipsychotics; Second-Generation Antipsychotics; Third-Generation Antipsychotics; Psychotherapies; Other Treatments
• 3) By Route of Administration: Oral; Injectables
• Subsegments:
• 1) By Catatonic Schizophrenia: Waxy Flexibility; Stupor; Agitation; Catatonic Excitement
• 2) By Paranoid Schizophrenia: Delusions Of Persecution; Auditory Hallucinations; Paranoid Ideation
• 3) By Undifferentiated Schizophrenia: Symptoms Not Specific To Other Types; Mixed Symptoms Of Schizophrenia
• 4) By Hebephrenic Schizophrenia (Disorganized Schizophrenia): Disorganized Behavior; Disorganized Speech; Emotional Flatness
• 5) By Residual Schizophrenia: History Of Schizophrenia With Low-Level Symptoms; Social Withdrawal; Mild Hallucinations Or Delusions
• 6) By Other Types: Schizoaffective Disorder; Brief Psychotic Disorder; Delusional Disorder
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline PLC; Takeda Pharmaceutical Company; Eli Lilly and Company; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Amgen Inc.; Otsuka Holdings Co. Ltd.; Biogen Inc.; Daiichi Sankyo Co. Ltd.; Astellas Pharma Inc.; Sumitomo Dainippon Pharma Co. Ltd.; Mitsubishi Tanabe Pharma Corporation; Recordati SpA; Lundbeck A/S; Neurocrine Biosciences Inc.; Torrent Pharmaceutical Ltd.; Alkermes PLC; Indivior PLC; Vanda Pharmaceuticals Inc.; Intra-Cellular Therapies Inc.; Axsome Therapeutics Inc.; PsychoGenics Inc.; Karuna Therapeutics Inc.; Minerva Neurosciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizophrenia Market Characteristics

3. Schizophrenia Market Trends And Strategies

4. Schizophrenia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Schizophrenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizophrenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizophrenia Market Growth Rate Analysis
• 5.4. Global Schizophrenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizophrenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizophrenia Total Addressable Market (TAM)

6. Schizophrenia Market Segmentation

• 6.1. Global Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Catatonic Schizophrenia
• Paranoid Schizophrenia
• Undifferentiated Schizophrenia
• Hebephrenic Schizophrenia
• Residual Schizophrenia
• Other Types
• 6.2. Global Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Antipsychotics
• Second-Generation Antipsychotics
• Third-Generation Antipsychotics
• Psychotherapies
• Other Treatments
• 6.3. Global Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• 6.4. Global Schizophrenia Market, Sub-Segmentation Of Catatonic Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Waxy Flexibility
• Stupor
• Agitation
• Catatonic Excitement
• 6.5. Global Schizophrenia Market, Sub-Segmentation Of Paranoid Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Delusions Of Persecution
• Auditory Hallucinations
• Paranoid Ideation
• 6.6. Global Schizophrenia Market, Sub-Segmentation Of Undifferentiated Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptoms Not Specific To Other Types
• Mixed Symptoms Of Schizophrenia
• 6.7. Global Schizophrenia Market, Sub-Segmentation Of Hebephrenic Schizophrenia (Disorganized Schizophrenia), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disorganized Behavior
• Disorganized Speech
• Emotional Flatness
• 6.8. Global Schizophrenia Market, Sub-Segmentation Of Residual Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• History Of Schizophrenia With Low-Level Symptoms
• Social Withdrawal
• Mild Hallucinations Or Delusions
• 6.9. Global Schizophrenia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Schizoaffective Disorder
• Brief Psychotic Disorder
• Delusional Disorder

7. Schizophrenia Market Regional And Country Analysis

• 7.1. Global Schizophrenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizophrenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizophrenia Market

• 8.1. Asia-Pacific Schizophrenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizophrenia Market

• 9.1. China Schizophrenia Market Overview
• 9.2. China Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizophrenia Market

• 10.1. India Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizophrenia Market

• 11.1. Japan Schizophrenia Market Overview
• 11.2. Japan Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizophrenia Market

• 12.1. Australia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizophrenia Market

• 13.1. Indonesia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizophrenia Market

• 14.1. South Korea Schizophrenia Market Overview
• 14.2. South Korea Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizophrenia Market

• 15.1. Western Europe Schizophrenia Market Overview
• 15.2. Western Europe Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizophrenia Market

• 16.1. UK Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizophrenia Market

• 17.1. Germany Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizophrenia Market

• 18.1. France Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizophrenia Market

• 19.1. Italy Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizophrenia Market

• 20.1. Spain Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizophrenia Market

• 21.1. Eastern Europe Schizophrenia Market Overview
• 21.2. Eastern Europe Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizophrenia Market

• 22.1. Russia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizophrenia Market

• 23.1. North America Schizophrenia Market Overview
• 23.2. North America Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizophrenia Market

• 24.1. USA Schizophrenia Market Overview
• 24.2. USA Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizophrenia Market

• 25.1. Canada Schizophrenia Market Overview
• 25.2. Canada Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizophrenia Market

• 26.1. South America Schizophrenia Market Overview
• 26.2. South America Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizophrenia Market

• 27.1. Brazil Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizophrenia Market

• 28.1. Middle East Schizophrenia Market Overview
• 28.2. Middle East Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizophrenia Market

• 29.1. Africa Schizophrenia Market Overview
• 29.2. Africa Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizophrenia Market Competitive Landscape And Company Profiles

• 30.1. Schizophrenia Market Competitive Landscape
• 30.2. Schizophrenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Schizophrenia Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline PLC
• 31.3. Takeda Pharmaceutical Company
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Amgen Inc.
• 31.8. Otsuka Holdings Co. Ltd.
• 31.9. Biogen Inc.
• 31.10. Daiichi Sankyo Co. Ltd.
• 31.11. Astellas Pharma Inc.
• 31.12. Sumitomo Dainippon Pharma Co. Ltd.
• 31.13. Mitsubishi Tanabe Pharma Corporation
• 31.14. Recordati SpA
• 31.15. Lundbeck A/S

32. Global Schizophrenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizophrenia Market

34. Recent Developments In The Schizophrenia Market

35. Schizophrenia Market High Potential Countries, Segments and Strategies

• 35.1 Schizophrenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizophrenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizophrenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer